CN1080115C - Elemi olefine injecta and its preparation - Google Patents
Elemi olefine injecta and its preparation Download PDFInfo
- Publication number
- CN1080115C CN1080115C CN98116563A CN98116563A CN1080115C CN 1080115 C CN1080115 C CN 1080115C CN 98116563 A CN98116563 A CN 98116563A CN 98116563 A CN98116563 A CN 98116563A CN 1080115 C CN1080115 C CN 1080115C
- Authority
- CN
- China
- Prior art keywords
- elemene
- injection
- propylene glycol
- preparation
- gram
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 240000005209 Canarium indicum Species 0.000 title 1
- 239000004862 elemi Substances 0.000 title 1
- OPFTUNCRGUEPRZ-QLFBSQMISA-N (-)-beta-elemene Chemical compound CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 claims abstract description 83
- OPFTUNCRGUEPRZ-UHFFFAOYSA-N (+)-beta-Elemen Natural products CC(=C)C1CCC(C)(C=C)C(C(C)=C)C1 OPFTUNCRGUEPRZ-UHFFFAOYSA-N 0.000 claims abstract description 82
- 238000002347 injection Methods 0.000 claims abstract description 37
- 239000007924 injection Substances 0.000 claims abstract description 37
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 63
- -1 polyoxyethylene Polymers 0.000 claims description 25
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000008215 water for injection Substances 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 8
- 239000001913 cellulose Substances 0.000 claims description 7
- 229920002678 cellulose Polymers 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 239000012982 microporous membrane Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 238000007789 sealing Methods 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 238000004659 sterilization and disinfection Methods 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 4
- 239000000178 monomer Substances 0.000 claims description 4
- YZSJUQIFYHUSKU-UHFFFAOYSA-N ethanol;propane-1,2-diol Chemical compound CCO.CC(O)CO YZSJUQIFYHUSKU-UHFFFAOYSA-N 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 6
- 230000001093 anti-cancer Effects 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 3
- 206010006187 Breast cancer Diseases 0.000 abstract description 2
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 abstract 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 abstract 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 abstract 1
- 208000009956 adenocarcinoma Diseases 0.000 abstract 1
- 230000007794 irritation Effects 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- QDUJKDRUFBJYSQ-UHFFFAOYSA-N alpha-elemene Natural products CC(C)C1=CC(=C(C)C)CCC1(C)C=C QDUJKDRUFBJYSQ-UHFFFAOYSA-N 0.000 description 6
- MXDMETWAEGIFOE-CABCVRRESA-N delta-elemene Chemical compound CC(C)C1=C[C@H](C(C)=C)[C@@](C)(C=C)CC1 MXDMETWAEGIFOE-CABCVRRESA-N 0.000 description 6
- RVOXATXFYDNXRE-UHFFFAOYSA-N gamma-elemene Natural products CC(=C1CCC(C)(C(C1)C(=C)C)C(=C)C)C RVOXATXFYDNXRE-UHFFFAOYSA-N 0.000 description 6
- BQSLMQNYHVFRDT-CABCVRRESA-N (-)-gamma-Elemene Natural products CC(C)=C1CC[C@](C)(C=C)[C@@H](C(C)=C)C1 BQSLMQNYHVFRDT-CABCVRRESA-N 0.000 description 3
- VMYXUZSZMNBRCN-AWEZNQCLSA-N Curcumene Natural products CC(C)=CCC[C@H](C)C1=CC=C(C)C=C1 VMYXUZSZMNBRCN-AWEZNQCLSA-N 0.000 description 3
- 241000628997 Flos Species 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- QDUJKDRUFBJYSQ-OAHLLOKOSA-N elemene Chemical compound CC(C)C1=CC(=C(C)C)CC[C@@]1(C)C=C QDUJKDRUFBJYSQ-OAHLLOKOSA-N 0.000 description 3
- BQSLMQNYHVFRDT-LSDHHAIUSA-N gamma-elemene Chemical compound CC(C)=C1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 BQSLMQNYHVFRDT-LSDHHAIUSA-N 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- MXDMETWAEGIFOE-UHFFFAOYSA-N rac-delta-elemene Natural products CC(C)C1=CC(C(C)=C)C(C)(C=C)CC1 MXDMETWAEGIFOE-UHFFFAOYSA-N 0.000 description 3
- VMYXUZSZMNBRCN-UHFFFAOYSA-N α-curcumene Chemical compound CC(C)=CCCC(C)C1=CC=C(C)C=C1 VMYXUZSZMNBRCN-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001673954 Magnolia sieboldii Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a new anticancer medicine elemene injection and a preparation method thereof, which is an improved medicine based on the existing elemene injection and a method for the improved medicine. The elemene of the present invention and isomers of the elemene are mixed with trimethylene glycol and Cremophorel to be stirred, heated, filtered, packaged, inflated with nitrogen, sealed by fusing and sterilized to be prepared into an injection. The present invention has the advantages of stable preparations and exact anticancer effects, particularly overcomes the disadvantage of great irritation of the existing elemene injection and has obvious curative effects on neuralgia tumor, pulmonary adenocarcinoma, breast cancer, nasopharyngeal cancer, etc.
Description
The present invention relates to a kind of injection of PTS elemene and various isomerss thereof and preparation method thereof.
Elemene is a kind of sesquiterpenoids that is present in the certain plants, nineteen fifty-three, the France scholar found elemene, elemene has been extracted in nineteen eighty-three Chinese scholar Guo Yong field etc. first in warm Rhizoma Curcumae, continue intelligent reported first during the same year elemene have active anticancer.Afterwards, the anticancer research of elemene has successively been included country " the Seventh Five-Year Plan ", " eight or five ", " 95 " Program for Tackling Key Problems in.
Elemene, Latin is called ELEMENUM, English name Elemene, chemical name 1-methyl isophthalic acid-vinyl-2,4-diisopropyl cyclohexane extraction.Molecular formula is C
15H
24Have many isomers to exist, and major part have active anticancer.Topmost have α-elemene, beta-elemene, δ-elemene, γ-elemene and curcumene and a Flos Caryophylli alkene etc.Elemene and various isomer thereof are present in the various plants, are example with the elemene, have separated obtaining from Radix Ginseng, Magnolia sieboldii, warm Rhizoma Curcumae, Herba Cymbopogonis Citrari.
The PTS elemene injection that China develops was voluntarily obtained New Drug Certificate in 93 years, and put into serial production listing and be applied to clinically, faced art and had shown curative effect and the potential DEVELOPMENT PROSPECT that it is good in using.But because the granule of the Emulsion of listing itself is big, poor stability, the indication of approval only limits to carcinous breast internal organs water, limited clinical application range greatly, and its zest is big, patient is difficult to accept, and often stimulates the therapy discontinued of having to because of not tolerating.How to work out a kind of can intravenous applications, bland elemene novel form becomes key subjects.
It is the elemene injection of cosolvent that Dalian Inst. of Medical Science once developed with the tween 80, and the cerebral glioma of intravenous applications treatment clinically, evident in efficacy.Yet the shortcoming of this dosage form maximum is that tween 80 content surpasses national regulation, has haemolysis to take place in the clinical practice, and country can not accept the new drug declaration.Although at this problem, carried out more than ten years to reduce the tween 80 Study on content, eventually can not the declaration new drug because of there not being big progress.
Above-mentioned two kinds of dosage forms of elemene have limited clinical practice greatly because of there being all drawbacks, develop new dosage form, and it is the task of top priority that the PTS elemene that China is developed voluntarily benefits extensive patients.
The object of the present invention is to provide a kind of be applicable to venoclysis, zest is humble, overcome haemolysis, contained supplementary product consumption meets elemene injection of national requirements and preparation method thereof.A large amount of isomers that elemene is provided simultaneously are that molecular formula is C
15H
24The preparation method of compound injection liquid.
Elemene injection provided by the invention, its component are respectively elemene, reach adjuvant propylene glycol polyoxyethylene ricinoleidin 35 (Cremophor EL) and waters for injection.The ratio of various components in injection can be elemene 0.01-0.05 grams per milliliter, propylene glycol 0.13-0.23 grams per milliliter, polyoxyethylene ricinoleidin 35 is the 0.15-0.25 grams per milliliter, all the other are water for injection, each proportionate relationship of organizing each as shown in the formula: the concentration of establishing the injection elemene is x, then the amount of elemene is the 10x gram, propylene glycol is 120+20x ± 10 grams, polyoxyethylene ricinoleidin 35 is 140+20x ± 10 grams, all the other are with water for injection to 1000 milliliter, and said elemene can comprise the monomer of the various isomers of elemene or the mixing of various isomers.
In the component of elemene injection, can use ethanol equivalent replacement propylene glycol.
Elemene injection preparation method provided by the invention is, extraction 10-50 gram elemene restrains the polyoxyethylene ricinoleidin 35 that is heated to 50-60 ℃ with 150-250 to be mixed, fully stir, adding 130-230 gram propylene glycol is stirred to clear and bright fully, add again and be preheated to 50-60 ℃ water for injection to 1000 milliliter, homogenizer is stirred to clear and bright, cellulose mixture fat filtering with microporous membrane, embedding are in the peace bottle, fill nitrogen, sealing by fusing, 100 ℃ of rotation steriliser steam sterilizations 30 minutes promptly get the elemene injection of 1-5%.
Said elemene can comprise the monomer of the various isomers of elemene, as α-elemene, beta-elemene, δ-elemene, γ-elemene, and elemene isomer or various monomeric mixing such as curcumene and Flos Caryophylli alkene, said propylene glycol can be used Party B's alcohol equivalent replacement.
The elemene injection preparation method of confession of the present invention also can change the concentration of elemene according to different patients' needs between 1%-10%.
Preparation method of the present invention is simple, supplementary material is easy to get, cosolvent polyoxyethylene ricinoleidin 35 in the adjuvant is pharmaceutic adjuvants of at present domestic and international extensive use, because the molecule and the elemene interaction of molecules of polyoxyethylene ricinoleidin 35, formed the class clathrate, make elemene have slow-releasing, and reduced zest, prolonged the medicine holdup time in vivo, thereby improved curative effect, preparation method of the present invention is not only applicable to elemene, and is applicable to α-elemene, beta-elemene, δ-elemene, γ-elemene, and the isomer of elemenes such as curcumene and Flos Caryophylli alkene.The maximum characteristics of the elemene injection of the present invention preparation are: can venoclysises, enlarged the indication scope; Reduced zest, made the patient can continuous use; Kept the effect that the elemene toxic and side effects is low, protect body's immunity.Evident in efficacy to cerebral glioma, meningioma, breast carcinoma, adenocarcinoma of lung, cancer of pancreas, nose rouge cancer etc.Life-time service this product has no effect to functions such as blood phase, liver,spleen,kidneys, helps clinical expansion and uses.
Elemene injection is colourless or little yellow transparent solution, and pH5.5-6.5 can preserve under the room temperature more than 2 years, 10 milliliters in every peace bottle, and intravenous drip is dissolved in the normal saline of 250-500 milliliter or 5% glucose with 4-8 mg/kg dosage and slowly instils.Owing to contain polyoxyethylene ricinoleidin 35, anaphylaxis may appear in individual patient, therefore, should do skin test before using this medicine, or use antiallergic agent in advance.
The embodiment of the invention is as follows:
Embodiment one
Elemene content meets the WS-049 of portion (X-041)-96 (1) standard more than 90%, and polyoxyethylene ricinoleidin 35 meets the U.S. and Deutscher Arzneibucs standard, and propylene glycol meets USP standard.Claim, measure above-mentioned former, adjuvant according to quantity: 10 gram elemenes, 35,140 milliliters of propylene glycol of 160 gram polyoxyethylene ricinoleidins.The polyoxyethylene ricinoleidin 35 that is preheated to 50-60 ℃ is mixed with elemene, fully stir, add propylene glycol and be stirred to clear and brightly fully, add the water for injection to 1000 milliliter that is preheating to 50-60 ℃ again.Homogenizer is stirred to clear and bright, cellulose mixture fat filtering with microporous membrane, and embedding was filled 100 ℃ in nitrogen, sealing by fusing, rotation steriliser steam sterilization 30 minutes in peace bottle.Promptly get 1% elemene injection.
Embodiment two
Used former, adjuvant claims, measures 20 gram elemenes according to quantity with implementation method one, 180 gram 35,160 milliliters of propylene glycol of polyoxyethylene ricinoleidin (proportion is 1).The polyoxyethylene ricinoleidin 35 that is preheated to 50-60 ℃ is mixed with elemene, fully stir, add propylene glycol and be stirred to clear and brightly fully, add the water for injection to 1000 milliliter that is preheating to 50-60 ℃ again.Homogenizer is stirred to clear and bright, cellulose mixture fat filtering with microporous membrane, and embedding was filled 100 ℃ in nitrogen, sealing by fusing, rotation steriliser steam sterilization 30 minutes in peace bottle.Promptly get 2% elemene injection.
Embodiment three
Beta-elemene content is more than 95%, and polyoxyethylene ricinoleidin 35 meets the U.S. and Deutscher Arzneibucs standard, and propylene glycol meets USP standard.Claim, measure above-mentioned former, adjuvant according to quantity: 10 gram beta-elemenes, 155 gram 35,130 milliliters of propylene glycol of polyoxyethylene ricinoleidin (proportion is 1).The polyoxyethylene ricinoleidin 35 that is preheated to 50-60 ℃ is mixed with elemene, fully stir, adding propylene glycol is stirred to clear and bright fully, add the water for injection to 1000 milliliter be preheating to 50-60 ℃ again, homogenizer is stirred to clear and bright, cellulose mixture fat filtering with microporous membrane, embedding filled 100 ℃ in nitrogen, sealing by fusing, rotation steriliser steam sterilization 30 minutes in peace bottle.Promptly get 1% beta-elemene injection.
Embodiment four
Used former, adjuvant is with implementation method three, claim, measure 20 gram beta-elemenes according to quantity, 170 gram polyoxyethylene ricinoleidins 35,150 milliliters of propylene glycol (proportion is 1), the polyoxyethylene ricinoleidin 35 that is preheated to 50-60 ℃ is mixed with elemene, fully stir, adding propylene glycol is stirred to clear and bright fully, add the water for injection to 1000 milliliter be preheating to 50-60 ℃ again, homogenizer is stirred to clear and bright, cellulose mixture fat filtering with microporous membrane, embedding filled 100 ℃ in nitrogen, sealing by fusing, rotation steriliser steam sterilization 30 minutes in peace bottle.Promptly get 2% beta-elemene injection.
Embodiment five
Elemene content meets WS-049 promulgated by the ministries or commissions of the Central Government (X-041)-96 (1) standard more than 90%, and polyoxyethylene ricinoleidin 35 meets the U.S. and Deutscher Arzneibucs standard, and ethanol meets USP standard.Claim, measure above-mentioned former, adjuvant according to quantity: 10 gram elemenes, 35,130 milliliters of ethanol of 160 gram polyoxyethylene ricinoleidins.The polyoxyethylene ricinoleidin 35 that is preheated to 50-60 ℃ is mixed with elemene, fully stir, adding ethanol is stirred to clear and bright fully, add the water for injection to 1000 milliliter be preheating to 50-60 ℃ again, homogenizer is stirred to clear and bright, cellulose mixture fat filtering with microporous membrane, embedding filled 100 ℃ in nitrogen, sealing by fusing, rotation steriliser steam sterilization 30 minutes in peace bottle.Promptly get 1% elemene injection.
Claims (7)
1, a kind of elemene injection is characterized in that the component of injection is respectively elemene, and the adjuvant propylene glycol, polyoxyethylene ricinoleidin 35 and water for injection.
2, elemene injection according to claim 1, it is characterized in that the ratio of each component is respectively elemene 0.01-0.05 grams per milliliter in the injection, propylene glycol 0.13-0.23 grams per milliliter, polyoxyethylene ricinoleidin 35 is the 0.15-0.25 grams per milliliter, all the other are water for injection, proportionate relationship between each component as shown in the formula: the concentration of establishing the injection elemene is x, then the amount of elemene is that 10x gram, propylene glycol are that 120+20x ± 10 grams, polyoxyethylene ricinoleidin 35 are 140+20x ± 10 grams, and all the other are with water for injection to 1000 milliliter.
3, elemene injection according to claim 1 and 2 is characterized in that said elemene comprises the mixing of the monomer or the various isomery colour solids of its various isomers.
4, claim 1 or 2 described elemene injections is characterized in that the propylene glycol ethanol equivalent replacement in the injection.
5, the preparation method of the described elemene injection of claim 1, it is characterized in that getting 10-50 gram elemene restrains the polyoxyethylene ricinoleidin 35 that is heated to 50-60 ℃ with 150-250 and mixes, fully stir, adding 130-230 gram propylene glycol is stirred to clear and bright fully, add again and be preheated to 50-60 ℃ water for injection to 1000 milliliter, homogenizer is stirred to clear and bright, cellulose mixture fat filtering with microporous membrane, embedding is in the peace bottle, fill 100 ℃ in nitrogen, sealing by fusing, rotation steriliser steam sterilization 30 minutes, and promptly got the elemene injection of 1-5%.
6, the preparation method of elemene injection according to claim 5 is characterized in that said elemene comprises the monomer or the various monomeric mixing of elemene and structure body thereof.
7, the preparation method of elemene injection according to claim 5 is characterized in that with ethanol equivalent replacement propylene glycol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98116563A CN1080115C (en) | 1998-08-12 | 1998-08-12 | Elemi olefine injecta and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98116563A CN1080115C (en) | 1998-08-12 | 1998-08-12 | Elemi olefine injecta and its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1244389A CN1244389A (en) | 2000-02-16 |
| CN1080115C true CN1080115C (en) | 2002-03-06 |
Family
ID=5225148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98116563A Expired - Lifetime CN1080115C (en) | 1998-08-12 | 1998-08-12 | Elemi olefine injecta and its preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1080115C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102998409A (en) * | 2012-12-19 | 2013-03-27 | 石药集团远大(大连)制药有限公司 | Method for determining content of delta-elemene |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100434066C (en) * | 2002-04-17 | 2008-11-19 | 谢恬 | Curcuma longa extract injection, and preparing process and use thereof |
| EP1773741A4 (en) * | 2004-07-07 | 2008-07-09 | Long Range Internat Usa Ltd In | Synthesis of (-)-beta-elemene, (-)-beta-elemenal, (-)-beta-elemenol, (-)-beta-elemene fluoride and their analogues, intermediates and composition and uses thereof |
| CN100457096C (en) * | 2005-11-07 | 2009-02-04 | 刘玉辉 | An elemene formulation and preparation method thereof |
| CN1981749B (en) * | 2005-12-13 | 2012-12-05 | 石药集团远大(大连)制药有限公司 | Use of beta-elemene for inhibiting cerebrovascular endothelial cell |
| CN101756900B (en) * | 2010-02-25 | 2012-05-30 | 谢恬 | Elemene micro-emulsion |
| CN101810593B (en) | 2010-05-10 | 2012-07-18 | 谢恬 | Elemene sustained-release tablets |
| CN112315901B (en) * | 2019-07-17 | 2022-10-25 | 四川弘合生物科技有限公司 | Concentrated solution for injection and preparation method thereof |
| CN111135143B (en) * | 2020-01-19 | 2021-12-14 | 齐鲁工业大学 | Beta-elemene self-microemulsion and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1076613A (en) * | 1993-02-15 | 1993-09-29 | 大连金港制药有限公司 | Elemene emulsion injection and preparation method thereof |
-
1998
- 1998-08-12 CN CN98116563A patent/CN1080115C/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1076613A (en) * | 1993-02-15 | 1993-09-29 | 大连金港制药有限公司 | Elemene emulsion injection and preparation method thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102998409A (en) * | 2012-12-19 | 2013-03-27 | 石药集团远大(大连)制药有限公司 | Method for determining content of delta-elemene |
| CN102998409B (en) * | 2012-12-19 | 2014-10-15 | 石药集团远大(大连)制药有限公司 | Method for determining content of delta-elemene |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1244389A (en) | 2000-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4708949A (en) | Therapeutic composition from plant extracts | |
| US4795742A (en) | Therapeutic composition from plant extracts | |
| CN1080115C (en) | Elemi olefine injecta and its preparation | |
| CN1060038C (en) | Elemene emulsion injection and its preparing process | |
| CN101669986A (en) | Compound gel preparation containing sophora alopecuroide oil | |
| CN1771968A (en) | Ursolic acid fat emulsion injection and its prepn | |
| CN1060344C (en) | Shumaining preparation for curing ischemic angiocardiopathy or cerebrovascular disease | |
| CN101028250A (en) | Garcinolic acid liposome and freezing-drying powdery preparation and its making method | |
| CN1067577C (en) | Preparation of isotomic Shengmei injecta | |
| Pinguet et al. | Effect of sodium chloride concentration and temperature on melphalan stability during storage and use | |
| CN1178119A (en) | Traditional Chinese medicine preparation for treating senile dementia | |
| CN100467025C (en) | Use of asiaticoside in preparation of medicines for diseases of cardio-cerebral blood vessels | |
| CN1990032B (en) | Composite intravenous injection emulsion of glossy ganoderma spore oil and coix seed oil and method for making same | |
| CN1698717B (en) | Chinese medicinal compound fat emulsion injection and its preparation method | |
| CN109758423A (en) | Use the method for vitamin K1 fat emulsion injection treatment coagulation disorders | |
| CN115554241A (en) | Micelle type vitamin K1 injection and preparation method and application thereof | |
| CN102018665B (en) | Strictosamide injection and preparation method thereof | |
| CN101507747B (en) | Preparation method of astragalus total-saponin sodium chloride injector | |
| CN112494502A (en) | Saccharide composition for enriching blood of blood deficiency syndrome | |
| CN1262942A (en) | Intravenous injection medicine for curing ischemic cerebrovascular disease and its preparing method | |
| CN1052412C (en) | Cancer therapy injection | |
| CN109806226A (en) | The purposes of vitamin K1 fat emulsion injection | |
| CN1931158A (en) | Compound emulsion of docetaxel and volatil Chinese medicine oil for intravenous injection and its prepn process | |
| CN1196263A (en) | Chinese medicinal preparation for treating leukemia | |
| CN1969939A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: DALIAN YUANDA PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: KEYU PHARMACEUTICAL SCIENCE + TECHNOLOGY DEVELOPMENT CO., LTD., DALIAN Effective date: 20040730 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20040730 Address after: 2808, room 116001, Yuanda building, 19 independence street, Liaoning, Dalian Patentee after: YUANDA PHARMACEUTICAL Co.,Ltd. DALIAN Address before: 116001, Liu Yuxin, No. 5, building 30-8, people's lane, Xigang District, Liaoning, Dalian Patentee before: KEYU PHARMACEUTICAL SCIENCE & |
|
| ASS | Succession or assignment of patent right |
Owner name: DALIAN YUANDA BUILDING CO., LTD. Free format text: FORMER OWNER: SHIJIAZHUANG PHARMACEUTICAL GROUP YUANDA (DALIAN) PHARMACEUTICAL CO., LTD. Effective date: 20130620 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C56 | Change in the name or address of the patentee |
Owner name: SHIJIAZHUANG PHARMACEUTICAL GROUP YUANDA (DALIAN) Free format text: FORMER NAME: YUANDA PHARMACEUTICAL CO., LTD., DALIAN |
|
| CP03 | Change of name, title or address |
Address after: 116000 No. 19, independence street, Zhongshan District, Liaoning, Dalian Patentee after: CSPC YUANDA (DALIAN) PHARMACEUTICAL CO.,LTD. Address before: 2808, room 116001, Yuanda building, 19 independence street, Liaoning, Dalian Patentee before: YUANDA PHARMACEUTICAL Co.,Ltd. DALIAN |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130620 Address after: 116000 No. 19, independence street, Zhongshan District, Liaoning, Dalian Patentee after: Dalian ambitious building Ltd. Address before: 116000 No. 19, independence street, Zhongshan District, Liaoning, Dalian Patentee before: CSPC YUANDA (DALIAN) PHARMACEUTICAL CO.,LTD. |
|
| DD01 | Delivery of document by public notice |
Addressee: Du Lihua Document name: Notification of Passing Examination on Formalities |
|
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 116000 No. 19, independence street, Zhongshan District, Liaoning, Dalian Patentee after: CSPC YUANDA (DALIAN) PHARMACEUTICAL CO.,LTD. Address before: 116000 No. 19, independence street, Zhongshan District, Liaoning, Dalian Patentee before: Dalian ambitious building Ltd. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20020306 |
|
| CX01 | Expiry of patent term |